Synthesis, structure, and second-order nonlinear optical properties of copper(II) and palladium(II) acentric complexes with N-salicylidene-N'-aroylhydrazine tridentate ligands.

Two new N-salicylidene-N'-aroylhydrazines ligands have been prepared: N-4-diethylaminosalicylidene-N'-4-nitrobenzoyl-hydrazine (L(1)) and N-4-diethylaminosalicylidene-N'-4-(4-nitrophenylethylidene)-benzoyl-hydrazine (L(2)). The ligands are properly functionalized with strong electron donor-acceptor groups and are of potential interest in second-order nonlinear optics (NLO). Dimeric copper(II) and palladium(II) complexes with L(1) and L(2) have been prepared, and, starting from these, mononuclear acentric adducts with pyridine as a further ligand have been prepared and characterized. The X-ray structures of three adducts are also reported. The NLO activity of the adducts has been determined by EFISH measurements giving mubeta values up to 1500 x 10(-48) esu for an incident wavelength of 1.907 microm.

Polynuclear coordination compounds of alkali metal ions with organic chromophores.

The crystal structures of sodium 4-([4-[N,N-bis(2-hydroxyethyl)amino]phenyl]diazenyl)benzoate 3.5-hydrate, Na+*C17H18N3O4-*3.5H2O, (I), and potassium 4-([4-[N,N-bis(2-hydroxyethyl)amino]phenyl]diazenyl)benzoate dihydrate, K+*C17H18N3O4-*2H2O, (II), are described. The results indicate an octahedral coordination around sodium in (I) and a trigonal prismatic coordination around potassium in (II). In both cases, coordination around the metal cation is achieved through O atoms of the water molecules and hydroxy groups of the chromophore. The organic conjugated part of the chromophore is approximately planar in (I), while a dihedral angle of 30.7 (2) degrees between the planes of the phenyl rings is observed in (II).

Compared kinetics of 2-(2,3-dihydro-5-acetoxy-4,6,7-trimethylbenzofuranyl) acetic acid (IRFI 016) and its active metabolite 2-(2,3-dihydro-5-hydroxy-4,6,7-trimethylbenzofuranyl) acetic acid (IRFI 005) in plasma and bronchial alveolar liquid in mice.

The concentration of 2-(2,3-dihydro-5-acetoxy-4,6,7-trimethylbenzofuranyl) acetic acid (IRFI 016) and its active metabolite 2-(2,3-dihydro-5-hydroxy-4,6,7-trimethylbenzofuranyl) acetic acid (IRFI 005) in bronchial alveolar liquid (BAL) and plasma of mice were studied. IRFI 016 and its active metabolite IRFI 005 are both present in BAL and plasma after oral administration of IRFI 016. In BAL no delay times were noted, in comparison with plasma, regarding Cmax time nor significant variation of t1/2 and the elimination constant (Kel). IRFI 016, orally administered, is very rapidly absorbed and, both in unaltered form and as its active metabolite, reaches the anatomic site where it carries out its principal pharmacological activity, according to the same kinetic course observed in plasma.